Revelation Biosciences said that it has closed a private placement financing with gross proceeds of $4.4 million that it plans to use for development of two pipeline products, including its REVTx-99 intranasal phosphorylated hexaacylated disaccharide (PHAD). REVTx-99 is in development for the treatment of viral respiratory infections, including COVID-19.
According to Revelation, some of the funds will be used to explore possible additional indications for REVTx-99. The other product set to benefit from the new funding is REVTx-501, a diagnostic for viral respiratory infections. The press release did not mention any intended use of the funds for development of REVTx-200, another intranasal candidate listed on the company’s web site that is described as “is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity” that is “based on the same technology used in REVTx-99.”
Read the Revelation Biosciences press release.
